• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转化生长因子-β受体:结构与功能

TGF-beta receptors: structure and function.

作者信息

Lin H Y, Moustakas A

机构信息

Program in Membrane Biology, Massachusetts General Hospital, Boston 02114.

出版信息

Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):337-49.

PMID:7920178
Abstract

The transforming growth factor beta (TGF-beta) superfamily of dimeric polypeptide growth factors regulate cell growth and differentiation and play important roles in embryonic development and the immune response. The molecular cloning of three types of high affinity cell-surface receptors (type I, type II and type III) for these growth factors provide insights into their poorly understood mechanisms of action. Here we focus on the structure of these receptors and on the complex interactions which occur between different receptors that are necessary for ligand-induced signal transduction. The type I and type II receptors are both related transmembrane serine/threonine kinase receptors which may hetero-oligomerize to transduce proper signals. The type III receptor modulates the binding of ligands to the signaling complex of type I and type II receptors. These findings suggest that serine/threonine phosphorylation and heteromeric receptor interactions are important elements of TGF-beta induced signaling.

摘要

二聚体多肽生长因子的转化生长因子β(TGF-β)超家族调节细胞生长和分化,并在胚胎发育和免疫反应中发挥重要作用。这些生长因子的三种高亲和力细胞表面受体(I型、II型和III型)的分子克隆为其作用机制的深入理解提供了线索,而这些机制此前了解甚少。在这里,我们重点关注这些受体的结构以及不同受体之间发生的复杂相互作用,这些相互作用是配体诱导信号转导所必需的。I型和II型受体都是相关的跨膜丝氨酸/苏氨酸激酶受体,它们可能异源寡聚化以转导适当的信号。III型受体调节配体与I型和II型受体信号复合物的结合。这些发现表明,丝氨酸/苏氨酸磷酸化和异源受体相互作用是TGF-β诱导信号转导的重要元素。

相似文献

1
TGF-beta receptors: structure and function.转化生长因子-β受体:结构与功能
Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):337-49.
2
An emerging complexity of receptors for transforming growth factor-beta.转化生长因子-β受体中一个新出现的复杂性问题。
Princess Takamatsu Symp. 1994;24:264-75.
3
Transforming growth factor-beta receptor expression on human skin fibroblasts: dimeric complex formation of type I and type II receptors and identification of glycosyl phosphatidylinositol-anchored transforming growth factor-beta binding proteins.人皮肤成纤维细胞上转化生长因子-β受体的表达:I型和II型受体的二聚体复合物形成以及糖基磷脂酰肌醇锚定的转化生长因子-β结合蛋白的鉴定
J Cell Physiol. 1998 Sep;176(3):553-64. doi: 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.0.CO;2-0.
4
Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.乳腺上皮中转化生长因子β II型受体的显性负干扰导致未生育小鼠的肺泡增生和分化。
Cell Growth Differ. 1998 Mar;9(3):229-38.
5
FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes.胚胎成纤维细胞和胸腺细胞中转化生长因子β受体I信号活性的调节不需要FKBP12。
Cell Growth Differ. 1998 Mar;9(3):223-8.
6
Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex.人TβR2胞外结构域与转化生长因子-β3复合物的晶体结构
Nat Struct Biol. 2002 Mar;9(3):203-8. doi: 10.1038/nsb766.
7
The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.在人前列腺癌细胞系LNCaP中,转化生长因子-β1(TGF-β1)信号传导并不需要传统的I型转化生长因子-β(TGF-β)受体。
Exp Cell Res. 1998 May 25;241(1):151-60. doi: 10.1006/excr.1998.4034.
8
Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation.转化生长因子-β介导的信号转导:一种具有广泛负调控的协同模式。
J Cell Biochem Suppl. 1998;30-31:111-22.
9
Ligand-induced dimerization of the extracellular domain of the TGF-beta receptor type II.配体诱导的II型转化生长因子β受体胞外域二聚化。
Biochem Biophys Res Commun. 1996 Jul 25;224(3):709-16. doi: 10.1006/bbrc.1996.1088.
10
Crossing Smads.交叉的Smad蛋白
Sci STKE. 2000 Mar 14;2000(23):re1. doi: 10.1126/stke.2000.23.re1.

引用本文的文献

1
-2 Regulates Liver Fibrosis through the TGF-β Signaling Pathway.-2 通过转化生长因子-β信号通路调节肝纤维化。
Cancers (Basel). 2021 Oct 21;13(21):5279. doi: 10.3390/cancers13215279.
2
O-GlcNAc stabilizes SMAD4 by inhibiting GSK-3β-mediated proteasomal degradation.O-GlcNAc 通过抑制 GSK-3β 介导的蛋白酶体降解稳定 SMAD4。
Sci Rep. 2020 Nov 16;10(1):19908. doi: 10.1038/s41598-020-76862-0.
3
MicroRNA-195a-5p inhibits mouse medullary thymic epithelial cells proliferation by directly targeting Smad7.微小RNA-195a-5p通过直接靶向Smad7抑制小鼠髓质胸腺上皮细胞增殖。
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):290-7. doi: 10.1093/abbs/gmv136. Epub 2016 Feb 1.
4
The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes.Alk-1和Alk-5在软骨细胞机械传感中的作用。
Cell Mol Biol Lett. 2014 Dec;19(4):659-74. doi: 10.2478/s11658-014-0220-6. Epub 2014 Nov 25.
5
NetSlim: high-confidence curated signaling maps.NetSlim:高可信度精心策划的信号转导图谱。
Database (Oxford). 2011 Sep 29;2011:bar032. doi: 10.1093/database/bar032. Print 2011.
6
Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.意大利进行性骨化性纤维发育不良患者ACVR1基因的突变分析:验证与进展
Eur J Hum Genet. 2009 Mar;17(3):311-8. doi: 10.1038/ejhg.2008.178. Epub 2008 Oct 1.
7
Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy.转化生长因子-β在实验性糖尿病神经病变中诱导细胞损伤。
Exp Neurol. 2008 Jun;211(2):469-79. doi: 10.1016/j.expneurol.2008.02.011. Epub 2008 Mar 2.
8
Increased expression of TGF-beta1 reduces tumor growth of human U-87 Glioblastoma Cells in vivo.转化生长因子β1(TGF-β1)表达增加可降低人U-87胶质母细胞瘤细胞在体内的肿瘤生长。
Cancer Immunol Immunother. 2006 Aug;55(8):918-27. doi: 10.1007/s00262-005-0083-9. Epub 2005 Sep 27.
9
Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.转化生长因子-β抑制剂逆转肿瘤诱导的免疫抑制作用
Invest New Drugs. 2003 Feb;21(1):21-32. doi: 10.1023/a:1022951824806.
10
Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer.转化生长因子β1及转化生长因子βⅡ型受体在胃癌中的作用
Korean J Intern Med. 2002 Sep;17(3):160-6. doi: 10.3904/kjim.2002.17.3.160.